Literature DB >> 18728351

Tiotropium bromide attenuates respiratory syncytial virus replication in epithelial cells.

Ken Iesato1, Koichiro Tatsumi, Kengo Saito, Takashi Ogasawara, Seiichiro Sakao, Yuji Tada, Yasunori Kasahara, Katsushi Kurosu, Nobuhiro Tanabe, Yuichi Takiguchi, Takayuki Kuriyama, Hiroshi Shirasawa.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) infection could be related to airway inflammation as well as exacerbation of chronic obstructive pulmonary disease (COPD). Tiotropium bromide decreases the frequency of exacerbation in patients with COPD; however, the mechanisms of tiotropium bromide to reduce the chances of exacerbation have not been defined. One potential mechanism could be that tiotropium bromide protects against RSV infection in epithelial cells.
OBJECTIVE: To examine whether tiotropium bromide affects RSV replication in HEp-2 cells.
METHODS: The supernatant titer of RSV was calculated by methylcellulose plaque assay after RSV innoculation. Intracellular RSV and ICAM-1 mRNA were measured by PCR. Syncytium formation was observed by light microscopy. Intracellular RSV fusion protein and RhoA protein were detected by Western blot analysis. Furthermore, RhoA activity, ICAM-1 expression and inflammatory cytokines in cultured supernatant were measured by binding assay, immunofluorescence staining and ELISA, respectively.
RESULTS: Tiotropium bromide decreased the supernatant titer of RSV, and it inhibited syncytium formation, RhoA activation and ICAM-1 expression. Moreover, it suppressed the production of IL-6 and IL-8 after RSV infection.
CONCLUSIONS: The antiviral effects of tiotropium bromide regarding RSV replication are partly due to inhibition of RhoA activity and ICAM-1 expression. Tiotropium bromide decreases RSV replication and may modulate airway inflammation by reducing the production of inflammatory cytokines. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18728351     DOI: 10.1159/000151729

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  10 in total

Review 1.  Asthma therapy and its effect on airway remodelling.

Authors:  Rachid Berair; Christopher E Brightling
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

Review 2.  The Use of Inhaled Corticosteroids to Prevent Acute Exacerbations of COPD: A Pro/Con Debate.

Authors:  Richard E K Russell; Ian Pavord
Journal:  Turk Thorac J       Date:  2019-04-25

Review 3.  Influencing the decline of lung function in COPD: use of pharmacotherapy.

Authors:  Ekaterina S Gladysheva; Atul Malhotra; Robert L Owens
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-06-03

4.  Oncolytic viral therapy for neuroblastoma cells with Sindbis virus AR339 strain.

Authors:  Ayako Takenouchi; Kengo Saito; Eriko Saito; Takeshi Saito; Tomoro Hishiki; Tadashi Matsunaga; Naohisa Isegawa; Hideo Yoshida; Naomi Ohnuma; Hiroshi Shirasawa
Journal:  Pediatr Surg Int       Date:  2015-08-23       Impact factor: 2.003

5.  Tiotropium Attenuates Virus-Induced Pulmonary Inflammation in Cigarette Smoke-Exposed Mice.

Authors:  Hannes Bucher; Matthias J Duechs; Cornelia Tilp; Birgit Jung; Klaus J Erb
Journal:  J Pharmacol Exp Ther       Date:  2016-03-25       Impact factor: 4.030

Review 6.  The role of bronchodilator treatment in the prevention of exacerbations of COPD.

Authors:  Jadwiga A Wedzicha; Marc Decramer; Terence A R Seemungal
Journal:  Eur Respir J       Date:  2012-07-26       Impact factor: 16.671

7.  Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.

Authors:  Manuel Mata; Isidoro Martinez; Jose A Melero; Herman Tenor; Julio Cortijo
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

Review 8.  Virus-induced exacerbations in asthma and COPD.

Authors:  Daisuke Kurai; Takeshi Saraya; Haruyuki Ishii; Hajime Takizawa
Journal:  Front Microbiol       Date:  2013-10-01       Impact factor: 5.640

9.  Tiotropium is Predicted to be a Promising Drug for COVID-19 Through Transcriptome-Based Comprehensive Molecular Pathway Analysis.

Authors:  Keunsoo Kang; Hoo Hyun Kim; Yoonjung Choi
Journal:  Viruses       Date:  2020-07-20       Impact factor: 5.048

Review 10.  Epithelial Barrier Dysfunction in Chronic Respiratory Diseases.

Authors:  François M Carlier; Charlotte de Fays; Charles Pilette
Journal:  Front Physiol       Date:  2021-06-24       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.